Therapeutic strategies for EGFR-mutated lung cancer

preview_player
Показать описание
Luis Raez, MD, FACP, FCCP, Memorial Healthcare System, Pembroke Pines, FL, provides an overview of management options for patient with non-small cell lung cancer (NSCLC), who have progressed on EGFR inhibitors. Half of patients will develop resistance to osimertinib via MET, HER2 or fusion mutations, which represent a great unmet need. Novel agents such as amivantamab, and lazertinib have showed encouraging efficacy in trials. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
  1. VJOncology
  2. Speaker: Luis Raez
  3. Institution: Memorial Healthcare System
  4. Event: PRIMO 2023
  5. Format: Interview
  6. Subject: Lung Cancer
Рекомендации по теме
Therapeutic strategies for 0:02:23

Therapeutic strategies for EGFR-mutated lung cancer

Emerging treatment strategies 0:01:30

Emerging treatment strategies in EGFR-mutant NSCLC: osimertinib combinations and beyond

Acquired EGFR resistance: 0:20:07

Acquired EGFR resistance: What are the current therapeutic strategies?

EGFR mutation positive 0:23:10

EGFR mutation positive tumors: Treatment strategies in front line and at relapse

Mechanisms of Resistance 0:21:09

Mechanisms of Resistance to EGFR TKI and New Treatment Strategies

EGFR inhibitors in 0:18:06

EGFR inhibitors in mutation (+) patients: Current therapeutic strategies in the frontline setting

Advancing Care for 0:53:55

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine Strategies

Dr. Piotrowska on 0:01:57

Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC

Trials in EGFR 0:10:38

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer

Current and novel 0:01:09

Current and novel treatment approaches for first-line EGFR-m NSCLC

The challenge of 0:01:26

The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC

New Treatment Option 0:01:57

New Treatment Option for EGFR Mutated Lung Cancer

Optimizing Therapy at 0:02:50

Optimizing Therapy at Progression of EGFR-Mutant NSCLC

Time for Even 0:58:24

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC

Management of EGFR-Mutant 1:18:11

Management of EGFR-Mutant Lung Cancer With Central Nervous System Metastases

Future Research and 0:20:38

Future Research and Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

Advances in managing 0:01:05

Advances in managing KRASG12C- and EGFR-mutated NSCLC

Targeting EGFR-positive NSCLC 0:01:25

Targeting EGFR-positive NSCLC with antibody-drug conjugates

2021 West Oncology 0:20:34

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2

Adjuvant therapy for 0:14:30

Adjuvant therapy for EGFR mutant NSCLC

Emerging Data in 0:07:08

Emerging Data in EGFR-Mutant Lung Cancer

EGFR Mutations in 0:04:10

EGFR Mutations in Advanced NSCLC - Targeted Therapies in Lung Cancer 2023

Current treatment recommendations 0:01:25

Current treatment recommendations and future directions for EGFR-mutant NSCLC

Sequential treatment with 0:06:28

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC